Anixa Biosciences Inc ANIX
We take great care to ensure that the data presented and summarized in this overview for Anixa Biosciences Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANIX
View all-
Vanguard Group Inc Valley Forge, PA1.39MShares$4.39 Million0.0% of portfolio
-
D.A. Davidson & Co.671KShares$2.11 Million0.02% of portfolio
-
Laird Norton Trust Company, LLC621KShares$1.96 Million0.26% of portfolio
-
Ubs Group Ag529KShares$1.67 Million0.0% of portfolio
-
Mission Wealth Management, LP510KShares$1.6 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA329KShares$1.04 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC217KShares$684,0160.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR166KShares$521,9580.02% of portfolio
-
Black Rock Inc. New York, NY160KShares$505,3100.0% of portfolio
-
State Street Corp Boston, MA112KShares$352,4850.0% of portfolio
Latest Institutional Activity in ANIX
Top Purchases
Top Sells
About ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Insider Transactions at ANIX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 22
2024
|
Lewis H Titterton Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+1.72%
|
$32,000
$2.58 P/Share
|
|
Jul 31
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
5,580
+0.62%
|
$16,740
$3.23 P/Share
|
|
Jul 30
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
21,646
+2.37%
|
$64,938
$3.06 P/Share
|
|
Jul 26
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
7,700
+0.88%
|
$23,100
$3.03 P/Share
|
|
Jul 26
2024
|
Arnold M Baskies Director |
BUY
Open market or private purchase
|
Direct |
5,000
+4.17%
|
$15,000
$3.09 P/Share
|
|
Jul 25
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
796
+0.09%
|
$1,592
$2.81 P/Share
|
|
Jun 14
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
4,000
+0.46%
|
$8,000
$2.68 P/Share
|
|
Jun 13
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
405
+0.05%
|
$810
$2.7 P/Share
|
|
Jun 11
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
7,102
+0.82%
|
$14,204
$2.66 P/Share
|
|
Jun 10
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
330
+0.04%
|
$660
$2.6 P/Share
|
|
Jun 07
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
10,738
+1.25%
|
$21,476
$2.52 P/Share
|
|
Jun 07
2024
|
Michael Catelani President, COO, & CFO |
BUY
Open market or private purchase
|
Direct |
6,250
+15.07%
|
$12,500
$2.4 P/Share
|
|
Jun 07
2024
|
Amit Kumar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+4.61%
|
$50,000
$2.41 P/Share
|
|
Apr 30
2024
|
Michael Catelani President, COO, & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,189
+3.94%
|
$2,378
$2.52 P/Share
|
|
Apr 09
2024
|
Lewis H Titterton Jr Director |
BUY
Open market or private purchase
|
Direct |
15,009
+1.76%
|
$45,027
$3.28 P/Share
|
|
Mar 15
2024
|
Arnold M Baskies Director |
BUY
Open market or private purchase
|
Direct |
10,000
+8.33%
|
$30,000
$3.63 P/Share
|
|
Mar 15
2024
|
Amit Kumar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+5.75%
|
$90,000
$3.22 P/Share
|
|
Oct 31
2023
|
Michael Catelani President, COO, & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,117
+3.87%
|
$2,234
$2.69 P/Share
|
|
Oct 10
2023
|
Lewis H Titterton Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+1.91%
|
$32,000
$2.58 P/Share
|
|
Jul 31
2023
|
Amit Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,800
-2.49%
|
$35,400
$3.57 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 16K shares |
|---|---|
| Open market or private purchase | 150K shares |
| Grant, award, or other acquisition | 1.19K shares |